NVAX NOVAVAX INC Disposals and divestitures 8-K Filing 2025 - Contract Termination On March 7, 2025, Novavax announced the termination of its advanced purchase agreement with Canada due to not receiving regulatory approval for its COVID-19 vaccine by the deadline, resulting in $576 million being recognized as product revenue in Q1 2025, while $28 million in advanced payments will be refunded to Canada.Get access to all SEC 8-K filings of the NOVAVAX INC